Skip to main content
. 2022 Sep 13;12:914385. doi: 10.3389/fonc.2022.914385

Figure 6.

Figure 6

Subgroup analysis for progression-free survival and overall survival stratified by type I+II PVTT (A, B) and type III PVTT (C, D). T+S, transarterial chemoembolization+sorafenib; T+S+ICIs, transarterial chemoembolization+sorafenib+immune checkpoint inhibitors; PVTT, portal vein tumor thrombus; type I, tumor thrombi involving segmental branches of portal vein or above; type II, tumor thrombi involving right/left portal vein; type III, tumor thrombi involving the main portal vein.